Related references
Note: Only part of the references are listed.Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
Shaoqing Huang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2022)
Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours
Juan Liu et al.
MOLECULAR ONCOLOGY (2022)
Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour
Charlotte Brinch et al.
CASE REPORTS IN ONCOLOGY (2021)
An Unexpected Response to Imatinib in a Wild-Type Gastrointestinal Stromal Tumor
Mathilde Gheysen et al.
ONCOLOGY RESEARCH AND TREATMENT (2020)
Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive
Mehmet Sitki Copur et al.
ONCOLOGY-NEW YORK (2020)
A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity
Mara Fornasarig et al.
JOURNAL OF PERSONALIZED MEDICINE (2020)
An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy
Nick Baniak et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2019)
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Cesar Serrano et al.
CLINICAL CANCER RESEARCH (2019)
Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA
Pieter A. Boonstra et al.
ONCOLOGIST (2019)
Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib
Margherita Nannini et al.
SCIENTIFIC REPORTS (2019)
Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview
S. Farag et al.
FAMILIAL CANCER (2018)
Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
Eunjung Yim et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2018)
Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review
Siyuan Tan et al.
DISEASE MARKERS (2018)
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate-or High-Risk Primary Gastrointestinal Stromal Tumor The PERSIST-5 Clinical Trial
Chandrajit P. Raut et al.
JAMA ONCOLOGY (2018)
Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients
Sheima Farag et al.
EUROPEAN JOURNAL OF CANCER (2017)
Familial gastrointestinal stromal tumors, lentigines, and cafe-au-lait macules associated with germline c-kit mutation treated with imatinib
Divya Gupta et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2017)
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
Chun-Nan Yeh et al.
ONCOTARGET (2017)
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2017)
Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
Gulgun Engin et al.
WORLD JOURNAL OF RADIOLOGY (2017)
Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib
Anant Ramaswamy et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review
Philippe Rochigneux et al.
CASE REPORTS IN ONCOLOGY (2017)
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
E. Ben-Ami et al.
ANNALS OF ONCOLOGY (2016)
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group
Anna Patrikidou et al.
EUROPEAN JOURNAL OF CANCER (2016)
Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor
Daniela Gasparotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha Mutated Gastrointestinal stromal Tumors
Changhoon Yoo et al.
CANCER RESEARCH AND TREATMENT (2016)
Familial and Multiple Gastrointestinal Stromal Tumors with Fair Response to a Half-dose of Imatinib
Shigeki Bamba et al.
INTERNAL MEDICINE (2015)
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis
Gloria Ravegnini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
In Vivo Imatinib Sensitivity in a Patient With GI Stromal Tumor Bearing a PDGFRA Deletion DIM842-844
Paul T. Fanta et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor
Guhyun Kang et al.
TARGETED ONCOLOGY (2015)
Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
Gianluca Spitaleri et al.
OncoTargets and Therapy (2015)
Familial Gastrointestinal Stromal Tumor Syndrome: Report of 2 Cases With KIT Exon 11 Mutation
Derek H. Jones et al.
CANCER CONTROL (2015)
Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
Thomas Grellety et al.
FUTURE SCIENCE OA (2015)
Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
Andrew S. Brohl et al.
CLINICAL SARCOMA RESEARCH (2015)
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
Christopher L. Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial
Ronald P. DeMatteo et al.
ANNALS OF SURGERY (2013)
Rare, Germline Mutation of KIT With Imatinib-Resistant Multiple GI Stromal Tumors and Mastocytosis
Richard A. Speight et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)
Sebastian Huss et al.
MODERN PATHOLOGY (2013)
Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503
Ning-Ning Liu et al.
LABORATORY INVESTIGATION (2013)
Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib
Elena Conca et al.
MOLECULAR ONCOLOGY (2013)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier et al.
CLINICAL CANCER RESEARCH (2012)
Gastrointestinal stromal tumours - an update for histopathologists
Newton A. C. S. Wong
HISTOPATHOLOGY (2011)
Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review
Antje-Friederike Pelz et al.
HUMAN PATHOLOGY (2011)
Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study
Palma Dileo et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Small-Intestinal Rhabdoid Gastrointestinal Stromal Tumor (GIST): Mutation Analysis and Clinical Implications of a Rare Morphological Variant
Joshua Anspach Hanson et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2011)
Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin
Yao-Yu Hsieh et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2011)
Gastrointestinal stromal tumours: origin and molecular oncology
Christopher L. Corless et al.
NATURE REVIEWS CANCER (2011)
Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy A Novel Form of Tumor Progression
Bernadette Liegl et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance
Tianhua Guo et al.
CLINICAL CANCER RESEARCH (2009)
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activate and resist: L576P-KIT in GIST
Elena Conca et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor
Song Zheng et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation
Barbara Dewaele et al.
CLINICAL CANCER RESEARCH (2008)
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours
J. Lasota et al.
HISTOPATHOLOGY (2008)
Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation
Agnieszka Wozniak et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: Report of a case
Tohru Utsunomiya et al.
SURGERY TODAY (2008)
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
S. Bauer et al.
ONCOGENE (2007)
Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11
Keisuke Kubota et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour
Florian Grabellus et al.
GUT (2007)
We should desist using RECIST, at least in GIST
Robert S. Benjamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation
Nami Nakagomi et al.
LABORATORY INVESTIGATION (2007)
Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: Preliminary experience from Chang Gung Memorial Hospital
Chun-Nan Yeh et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations
Florian Haller et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
CLINICAL CANCER RESEARCH (2007)
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity
Ellen Weisberg et al.
GASTROENTEROLOGY (2006)
Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment
Chun-Nan Yeh et al.
LANGENBECKS ARCHIVES OF SURGERY (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate
Chun-Nan Yeh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann et al.
CLINICAL CANCER RESEARCH (2006)
Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy
B Melichar et al.
INTERNAL MEDICINE (2005)
Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour
F Grimpen et al.
LANCET ONCOLOGY (2005)
Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis
K Hartmann et al.
GASTROENTEROLOGY (2005)
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall
P Pauwels et al.
HISTOPATHOLOGY (2005)
Gastrointestinal stromal tumour treated with neoadjuvant imatinib
MB Loughrey et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations
E Wardelmann et al.
LANCET ONCOLOGY (2005)
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
M Debiec-Rychter et al.
GASTROENTEROLOGY (2005)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2004)
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
E Tamborini et al.
GASTROENTEROLOGY (2004)
Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
T Wakai et al.
BRITISH JOURNAL OF CANCER (2004)
Metastatic gastrointestinal stromal tumor with an Exon 11 c-Kit mutation responding to the tyrosine kinase inhibitor imatinib
H Cho et al.
DIGESTIVE SURGERY (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors
S Hirota et al.
GASTROENTEROLOGY (2003)
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib:: a centre-based study of 17 patients
P Bümming et al.
BRITISH JOURNAL OF CANCER (2003)
Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors
H Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT
S Bauer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
DA Tuveson et al.
ONCOGENE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
